Transthyretin-Associated Amyloidosis Outcome Survey (THAOS)
Learn more about:
Related Clinical Trial
Prognostic Value of Echocardiographic Parameters Based on Machine Learning Approach
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects
Screening of ATTRwt in Patient With Advanced AV-Block Undergoing Pacemaker Implantation
The Effect of Trimetazidine on Mitochondrial Function, Myocardial Performance, and Invasive Hemodynamics in Patients Diagnosed With Wild-Type Transthyretin Cardiac Amyloidosis
Evuzamitide as SPECT/CT Imaging Agent for Diagnosis of Transthyretin Amyloidosis
Longitudinal Changes in Left and Right Ventricular Global Strain After Chemotherapy in Cardiac Light Chain Amyloidosis
Left Atrial Strain and Supraventricular Arrhythmia Burden in Cardiac Light Chain Amyloidosis Following Chemotherapy
Early Detection of Neuropathy in ATTRv
carDIo-ttranSSfOrm nucLEar Imaging Study
SGLT2 Inhibitors in ATTR
Analysis of the Instestinal Microbiome of Patients With Transthyretin Amyloidosis
Amyloidosis TTR Flow Reserve Evaluation
Autonomic Evaluation of Patients With Hereditary Amyloidotic Cardiomyopathy: Hereditary Amyloidotic Heart Disease
Imaging for the Evaluation of Transthyretin Cardiac Amyloidosis Prevalence of Patients Over 65 Hospitalized in Cardiology Wards (the IMPACT Study)
Exercise Effect on Transthyretin Stability
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Patients With Idiopathic Peripheral Neuropathy
The Effect of Tafamidis on Transthyretin Stabilization, Safety, Tolerability and Efficacy in Transthyretin Amyloid Polyneuropathy Patients
Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis
ION-682884 in Patients With TTR Amyloid Cardiomyopathy
The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients
A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Bern Cardiac Amyloidosis REgistry (B-CARE)
Unmasking the Prevalence of AC in an Unselected Echocardiographic Population
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN)
Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Patient-Reported Outcome Measures in Wild-Type and Variant Cardiac Transthyretin Amyloidosis
Quantitative Analysis of Myocardial Uptake of Bone Radiopharmaceuticals in Patients With Cardiac ATTR Amyloidosis
ATTR-Cardiomyopathy Stabilization Following Tafamidis Therapy
Global Prevalence of ATTR-CM in Participants With HFpEF
Penn Biobank Return of Research Results Program
Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
Open-Label Study of AG10 in Patients With Cardiomyopathy
Screening for Systemic Amyloidosis Via the Ligamentum Flavum
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant
Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers
Cardiac Amyloidosis Screening at Trigger Finger Release
Positron Emission Tomography / Magnetic Resonance Imaging in Aortic Stenosis
Effect of Radiotherapy on ATTR Cardiac Amyloidosis : a Proof of Concept Study
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
Prevalence of Wild-Type Transthyretin Cardiac Amyloidosis Among Patients Undergoing Carpal Tunnel Release Surgery – A Prospective Study
The Effect of Diflunisal on Familial Amyloidosis
Epidemiological Analysis for the Hereditary Transthytetin-related Amyloidosis (hATTR)
Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP)
Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR)
Expanding the Biomarkers in Familial Amyloid Neuropathy: MRI and Motor Unit Estimation by Electrophysiological Study
Transthyretin-Associated Amyloidosis Outcome Survey (THAOS)
Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy
Safety and Efficacy Study of Doxycycline/UrsoDeoxyCholicAcid on Disease Progression in ATTR Amyloidosis
The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin
HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
Open-Label Extension Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)
Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy
An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy
Study of SOM0226 in Familial Amyloid Polyneuropathy
Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis
Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology